File Download
  Links for fulltext
     (May Require Subscription)

Article: Comparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA Covid-19 vaccine: a prospective cohort study

TitleComparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA Covid-19 vaccine: a prospective cohort study
Authors
KeywordsCOVID-19
Vaccine safety
Pharmacovigilance
Epidemiology
Pediatrics
Issue Date2022
PublisherElsevier, published in association with International Society for Infectious Diseases. The Journal's web site is located at http://www.elsevier.com/locate/ijid
Citation
International Journal of Infectious Diseases, 2022, v. 116, p. 47-50 How to Cite?
AbstractObjectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. Results: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk. Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated.
Persistent Identifierhttp://hdl.handle.net/10722/309889
ISSN
2023 Impact Factor: 4.8
2023 SCImago Journal Rankings: 1.435
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, EWW-
dc.contributor.authorLeung, MTY-
dc.contributor.authorLau, LKW-
dc.contributor.authorLeung, J-
dc.contributor.authorLum, D-
dc.contributor.authorWong, RSM-
dc.contributor.authorLi, X-
dc.contributor.authorChui, CSL-
dc.contributor.authorWan, EYF-
dc.contributor.authorWong, CKH-
dc.contributor.authorChan, EWY-
dc.contributor.authorIp, P-
dc.contributor.authorWong, ICK-
dc.contributor.authorLai, FTT-
dc.date.accessioned2022-01-10T09:15:20Z-
dc.date.available2022-01-10T09:15:20Z-
dc.date.issued2022-
dc.identifier.citationInternational Journal of Infectious Diseases, 2022, v. 116, p. 47-50-
dc.identifier.issn1201-9712-
dc.identifier.urihttp://hdl.handle.net/10722/309889-
dc.description.abstractObjectives: Although clinical data have shown that the BNT162b2 vaccine, which is widely used in many countries, is safe and effective as a protection against the SARS-CoV-2 infection, extant research in adverse reactions using real-world data of various sociodemographic characteristics is scant. Methods: We conducted a prospective cohort study to compare age differences in self-reported reactogenicity of BNT162b2 in Hong Kong. A total of 1,516 participants were intensively followed up for two weeks following both doses of BNT162b2 vaccination, during which their basic demographic, health conditions, and medication information were collected. Results: Results from the generalized mixed model showed that compared with adults aged 18 to 59 years, older adults aged 60 years or above had a lower risk of adverse reactions and adolescents aged 12 to 17 years had a moderately higher risk. Conclusions: Results of this study should be informative to parents considering BNT162b2 vaccination for their children in that moderately increased reactogenicity compared with adults is anticipated.-
dc.languageeng-
dc.publisherElsevier, published in association with International Society for Infectious Diseases. The Journal's web site is located at http://www.elsevier.com/locate/ijid-
dc.relation.ispartofInternational Journal of Infectious Diseases-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID-19-
dc.subjectVaccine safety-
dc.subjectPharmacovigilance-
dc.subjectEpidemiology-
dc.subjectPediatrics-
dc.titleComparing self-reported reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA Covid-19 vaccine: a prospective cohort study-
dc.typeArticle-
dc.identifier.emailChan, EWW: edwwchan@hku.hk-
dc.identifier.emailLeung, MTY: mleungty@hku.hk-
dc.identifier.emailLau, LKW: llkw127@hku.hk-
dc.identifier.emailLeung, J: leungjcn@hku.hk-
dc.identifier.emailLum, D: dawnlum@hku.hk-
dc.identifier.emailWong, RSM: rosawong@hku.hk-
dc.identifier.emailLi, X: sxueli@hku.hk-
dc.identifier.emailChui, CSL: cslchui@hku.hk-
dc.identifier.emailWan, EYF: yfwan@hku.hk-
dc.identifier.emailWong, CKH: carlosho@hku.hk-
dc.identifier.emailChan, EWY: ewchan@hku.hk-
dc.identifier.emailIp, P: patricip@hku.hk-
dc.identifier.emailWong, ICK: wongick@hku.hk-
dc.identifier.emailLai, FTT: fttlai@hku.hk-
dc.identifier.authorityWong, RSM=rp02804-
dc.identifier.authorityLi, X=rp02531-
dc.identifier.authorityChui, CSL=rp02527-
dc.identifier.authorityWan, EYF=rp02518-
dc.identifier.authorityWong, CKH=rp01931-
dc.identifier.authorityChan, EWY=rp01587-
dc.identifier.authorityIp, P=rp01337-
dc.identifier.authorityWong, ICK=rp01480-
dc.identifier.authorityLai, FTT=rp02802-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1016/j.ijid.2021.12.354-
dc.identifier.pmid34965462-
dc.identifier.pmcidPMC8710238-
dc.identifier.scopuseid_2-s2.0-85122672518-
dc.identifier.hkuros331367-
dc.identifier.volume116-
dc.identifier.spage47-
dc.identifier.epage50-
dc.identifier.isiWOS:000789660900011-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats